Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Lirentelimab in Eosinophilic Gastritis and Duodenitis
NCT04620811Phase 3Completed
- Sponsor
- Allakos Inc.
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lirentelimab in eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD), sponsored by Allakos Inc. Primary endpoint: Safety and Tolerability of Lirentelimab up to 21 months. Started Dec 2020; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic gastritis (EG)eosinophilic duodenitis (EoD)
Beyond the preview
Go deeper on NCT04620811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620811.